07:42 AM EDT, 10/26/2026 (MT Newswires) -- New two-year follow-up results from a late-stage trial of pimicotinib showed that patients with tenosynovial giant cell tumor saw improvements in symptoms and joint function as early as week five, sustained through two years, Merck KGaA (MRK.F) said Monday. New analysis from the phase 3 Maneuver trial found that patients initially randomized to pimicotinib had mean changes from baseline at week 97 of 19.6% in range of motion, -3.9 in stiffness, -3.1 in pain, and +7.4 in physical function. The German science and technology company holds worldwide commercialization rights for pimicotinib, which was developed by Abbisko Therapeutics.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.